On May 8, 2003, Arrington, Kenneth L.; Fraley, Mark E.; Hartman, George D. published a patent.Safety of 6-Chloro-2,3-dihydro-1H-indole The title of the patent was Indolylquinolinone derivative tyrosine kinase inhibitors, preparation thereof, and therapeutic use. And the patent contained the following:
The invention provides indolylquinolinone compounds which inhibit, regulate, and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age-related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals. Preparation of selected compounds is described. The experimental process involved the reaction of 6-Chloro-2,3-dihydro-1H-indole(cas: 52537-00-5).Safety of 6-Chloro-2,3-dihydro-1H-indole
The Article related to indolylquinolinone derivative preparation tyrosine kinase inhibitor therapeutic, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Safety of 6-Chloro-2,3-dihydro-1H-indole
Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles